semaglutide
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making health decisions. Trial Headline and Key Outcome The phase-2 pediatric study of oral semaglutide delivered a 7.2% greater reduction in BMI-Z score compared with placebo, marking
semaglutide
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making health decisions. A Pill Instead of a Needle: What the Trial Shows Headline: The first phase-III oral semaglutide trial in adolescents slashes HbA1c by 1.8 % and
semaglutide
When I first reported on the metabolic revolution sparked by GLP-1 drugs for diabetes, I never imagined the same class could be a contender in the battle against Alzheimer’s. Yet the headline-grabbing results from a 2024 Phase 2 trial - a 30 % slowing of cognitive decline - demand a
semaglutide
Breaking news from the 2023 STEP-P trial: adolescents taking oral semaglutide shed an average of 9.3% of body weight in one year, dwarfing the 1.4% loss seen with placebo (p < 0.001). The same study recorded a 0.9% drop in HbA1c versus 0.2% on placebo